Medicaid GLP-1 coverage in Maryland, 2026.
What Maryland Medicaid actually covers for Wegovy, Zepbound, Ozempic and Mounjaro. Most state Medicaid programs still exclude weight-loss-indication GLP-1, but the diabetes path is covered nearly everywhere with prior authorization. Here is the current 2026 reality for Maryland.
Coverage summary
| Indication | Coverage |
|---|---|
| Wegovy (weight loss) | Limited |
| Zepbound (weight loss) | Limited |
| Ozempic / Mounjaro (type 2 diabetes) | Yes |
| Compounded semaglutide / tirzepatide | No |
Prior-authorization criteria
| Criterion | Value |
|---|---|
| PA burden | High |
| BMI threshold (weight-loss path) | BMI 35+ |
| Comorbidity required | Yes |
| Last PDL update reviewed | 2024-Q4 |
What this means in practice
Maryland HealthChoice MCOs cover Wegovy with strict PA for BMI 35+ plus at least one documented comorbidity. The state added this coverage in 2024. Diabetes coverage with PA is standard.
Managed-care organizations in Maryland (9 contracted)
Maryland Medicaid contracts with the following managed-care organizations. MCO formularies must meet or exceed the state PDL but can layer in additional criteria. Verify your assigned MCO's most recent PA policy before submitting.
- Aetna Better Health of Maryland
- CareFirst BlueCross BlueShield Community Health Plan
- Kaiser Permanente of the Mid-Atlantic States
- Maryland Physicians Care
- Priority Partners
- UnitedHealthcare Community Plan
Cash-pay alternatives if Medicaid does not cover you
If you do not meet the BMI 35 threshold with comorbidity, the diabetes path applies for T2D. See /best/cheapest/.
For ranked cash-pay options, see programs ranked by price and programs under $150 a month. For manufacturer patient-assistance routes that bypass insurance entirely, see every cost-reduction pathway in 2026.
Take it to your prescriber: PA letter library
If you qualify under one of the covered indications above, the prior-authorization route is the cheapest path. We maintain a PA letter library with templates for Aetna, Cigna, UnitedHealthcare, Anthem BCBS, Kaiser, Humana, Tricare, FEHB and Medicare Advantage, cross-indexed against six qualifying clinical pictures. Each template cites the plan's policy document, the qualifying ICD-10 codes and the registration-trial evidence.
If you have type 2 diabetes plus chronic kidney disease and established cardiovascular disease, the triple-indication evidence stack (FLOW + SELECT + SUSTAIN-6) is the strongest PA path in any state.
Other state Medicaid pages
See the full 51-state coverage table for the side-by-side view across every US state.
How we built this page
Compiled from each state Medicaid's published preferred drug list, PA criteria and PDL committee minutes. State Medicaid programs are not federally required to cover obesity drugs; the diabetes indication is covered nearly everywhere with PA. State-level data is point-in-time and shifts each PDL cycle. Always verify with your state Medicaid plan before relying on this page.
Last updated: 2026-05-23. We re-verify quarterly by checking each state Medicaid PDL and PA criteria. If you have recently had a different experience with Maryland Medicaid, email hello@glpchart.com with the details and we will re-verify.
